PharmAla Biotech signs a contract with InterVivo Solutions to validate new MDMA analogues


Start of proof-of-concept preclinical animal research on PharmAla’s patented ABA series
programmed MDXX compounds

VANCOUVERBEFORE CHRIST , March 3, 2022 /CNW/ – PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA), a biotechnology company focused on the research, development and manufacturing of MDXX-class pharmaceuticals, is pleased to to announce that the Company has initiated preclinical research on a new class of New Patented Chemical Entities (NCEs) at InterVivo Solutions.

PharmAla Biotech Inc. Logo (CNW Group/PharmAla Biotech Inc.)

“PharmAla’s goal is to create new drugs with improved toxicological profiles and expand the use cases and indications for these drugs. PharmAla’s series of ABA drug candidates are based on an MDXX class molecule that is not scheduled as a controlled substance in Canada,” noted Nick Kadych, CEO of PharmAla. “In InterVivo Solutions, we have found an excellent research partner to accelerate research to select the most promising drug from the ABA series and bring it to the clinical phase.”

InterVivo Solutions is a well-established preclinical contract research organization (CRO) with expertise in neuropsychiatric and neurological diseases. Together with Transpharmation, they form the largest Neuroscience boutique specializing in small and large animal CROs. InterVivo Solutions will study PharmAla’s new NCEs evaluating the pharmacological effects and toxicology of the molecules compared to traditional generic MDMA.

“InterVivo Solutions is proud to support PharmAla’s research efforts to develop novel entactogenic chemical entities with improved safety profiles. This safety-focused approach will provide key insights that will not only reduce the risks of their transition to clinical use, but will also improve our knowledge base. and understanding the key characteristics of this class of disruptive molecules,” added Mark Duxon, CEO of InterVivo Solutions.

For more information, please visit www.PharmAla.cawhere you can sign up to receive regular updates.

About Pharmala

PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development and manufacturing of MDXX-class molecules, including MDMA. PharmAla was founded with a dual purpose: to reduce the global backlog of clinical-grade generic MDMA to enable clinical trials and to develop new drugs in the same class. PharmAla is a “regulatory first” organization, formed on the principle that true success in the psychedelic industry will only be achieved through excellent relationships with regulators. Our team of dedicated professionals includes regulatory experts, scientists and biomanufacturing professionals. PharmAla has built what it believes to be North America first cGMP MDMA value chain, encompassing GMP manufacturing of active pharmaceutical ingredients (API) and formulation of pharmaceutical products. PharmAla’s research and development unit has also begun preclinical research on two patented New Chemical Entities (NCEs) based on MDXX-class molecules, with proof-of-concept research currently underway at University of Arkansas School of Medical Sciences of United States and at InterVivo Solutions in Canada. For more information, visit

About InterVivo Solutions/Transpharmaceutical

Recently merged, InterVivo Solutions (IVS)/Transpharmation(TPH) is the world leader in neuroscience contract research, offering translational research services focused on next-generation neuroscience drug discovery. IVS/TPH provides reference in vivo pharmacological models, drug metabolism, pharmacokinetics and early safety research studies for a global network of biopharmaceutical clients.

Neither the Canadian Securities Exchange nor its regulation services provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.


This press release contains “forward-looking information” within the meaning of applicable Canadian securities laws. These statements relate to future events or future performance. Use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “plan”, “estimate” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmAla’s current beliefs or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by PharmAla as of the date of the information and is subject to known and unknown risks, uncertainties and other factors that may cause actual results or events differ materially from those anticipated in the forward-looking information. The forward-looking information contained in this press release is made as of the date hereof, and PharmAla undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under “Risk Factors” in PharmAla’s MD&A which is available on PharmAla’s profile at www.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and does not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction

SOURCE PharmAla Biotech Inc.



View original content to download multimedia:


Comments are closed.